EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER AISBL
- Country
- Belgium
- Type
- Beneficiary
- Website
- www.eortc.be
- Grants received
- 29
Funding record
- 29 grants on record
- €22,974,449.20 awarded in total
- 2008–2023 years covered
This total adds up only the grants our sources publish. It is not the total funding this organisation has received.
Programmes
11 further grants are on record without a programme named by the source, or under a programme outside the largest shown here.
Frequent partners
Organisations funded alongside this one on two or more projects. Sharing a single project does not count. Some projects have as many as 195 participants, and appearing on the same list once is not a working relationship.
- THE UNIVERSITY OF MANCHESTER
- ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM
- INSTITUT GUSTAVE ROUSSY
- MEDIZINISCHE UNIVERSITAET WIEN
- FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI
- INSTITUT CURIE
- OSLO UNIVERSITETSSYKEHUS HF
- STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS
Calls from this organisation
No published calls from this organisation.
Grants received
- Lomustine with or without reirradiation for first progression of glioblastoma: a pragmatic randomized phase III study
- A PRAGMATIC CLINICAL STUDY OF NEOADJUVANT CHEMOTHERAPY FOLLOWED BY SURGERY VERSUS SURGERY ALONE FOR PATIENTS WITH HIGH RISK RETROPERITONEAL SARCOMA
- INTERMITTENT ANDROGEN DEPRIVATION THERAPY IN THE ERA OF ANDROGEN RECEPTOR PATHWAY INHIBITORS; A PHASE 3 PRAGMATIC RANDOMISED TRIAL
- COMPREHENSIVE CANCER INFRASTRUCTURES 4 EUROPE
- Quality of Life in Oncology: measuring what matters for cancer patients and survivors in Europe
- THE STRONG-AYA INITIATIVE: IMPROVING THE FUTURE OF YOUNG ADULTS WITH CANCER
- Providing cutting edge cancer research services across Europe
- Optimal treatment for patients with solid tumours in Europe through Artificial intelligence
- Next Generation Health Technology Assessment to support patient-centred, societally oriented, real-time decision-making on access and reimbursement for health technologies throughout Europe
- European Joint Programme on Rare Diseases
- Prostate Cancer DIagnOsis and TreatmeNt Enhancement through the Power of Big Data in EuRope
- Imaging Biomarkers (IBs) for Safer Drugs: Validation of Translational Imaging Methods in Drug Safety Assessment - Sofia ref.: 116106
- Healthcare Alliance for Resourceful Medicines Offensive against Neoplasms in HematologY - Sofia ref.: 116026
- Molecularly guided trials with specific treatment strategies in patients with advanced newly molecular defined subtypes of colorectal cancer (MoTriColor)
- Cancer treatment and monitoring through identification of circulating tumour cells and tumour related nucleic acids in blood
Data source
© European Union, 2026. Source: CORDIS. Reused under Commission Decision 2011/833/EU — CC BY 4.0.
We collected this from the source on .
Personal data of natural persons has been dissociated by quiescence.eu.
This service is not affiliated with, sponsored or endorsed by the data publishers.